Marina to Sell off Non-RNAi Asset to Cypress Bioscience | GenomeWeb

Marina Biotech said this week that it has signed an agreement to sell its patents and technology related to carbetocin, a long-acting analog of the hormone oxytocin, to Cypress Bioscience for an initial fee of $750,000 and potential milestones of up to $27 million.

According to Marina, the drug may potentially be used as an autism treatment. Nastech Pharmaceutical, the predecessor company of Marina, had advanced the compound through two phase I dose-escalation studies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

The US House of Representatives science committee has passed a bill to require NSF to ensure it only funds projects that are in the national interest.

DuPont teams with genome editing firm Caribou for agricultural applications of the technology.

A blogger reviews her experience learning about her gut microbiome by shipping a sample to uBiome.

In Science this week: ancient Ethiopian genome indicates greater Eurasian backflow into Africa, sequencing to diagnose cutaneous T cell lymphoma, and more.